drugset / Trial / NCT05839561

Monotherapy With Letrozole in Tubal Pregnancy

NCT05839561

Completed 22 enrolled Jagiellonian University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

It is hypothesized that the inhibition of estradiol production by letrozole may interfere with physiological effects of progesterone necessary to maintain the pregnancy. Treatment of tubal pregnancy with letrozole would allow to avoid the adverse effects of methotrexate (MTX) in women refusing surgery. The aim was to compare the effectiveness of letrozole with MTX in the management of tubal pregnancy.

Timeline

Start
2020-12-01
Primary completion
2022-12-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Letrozole Other / unclassified 5 mg Oral
Comparator Methotrexate Small molecule 100 mg Intravenous

Indications